Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Q4 FY2020 Earnings Presentation
24 slides from Dr. Lal Pathlabs's earnings presentation, May 18, 2020
Slide 1: Exchange filing cover letter for earnings presentation
May 18, 2020 National Stock Exchange of india Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai - 400 051 Mumbai- 400001 Subject: Earnings Presentation on Audited Financial Resul
Slide 2: Dr. Lal PathLabs Q4 & FY20 Results Presentation
Dr. Lal PathLabs Limited (DLPL) Q4 & FY20 Results Presentation May 18, 2020
Slide 3: Disclaimer
Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr. Lal PathLabs Limited (the “Company”) for use in presentat
Slide 4: Q4 FY20 Snapshot
Q4* FY20 Snapshot 0.2% 2.1% 5.9% INR 301.7 Cr ~ 4.4 mn Patients Tested ~11.2 mn Samples Processed Revenues Normalised EBITDA^ PAT Q4 INR 55.5 Cr Q4 INR 32.6 Cr FY20 INR 331.1 Cr FY20 INR 227.6 Cr * Q4 results have been adversely impacted due to COVID-19 pandemic and subsequent lockdown in the month
Slide 5: Table of Contents
Table of Contents Dr. Lal PathLabs – At a Glance 5 Overview of Dr. Lal PathLabs 6 Key Performance Highlights 10 Financials 11 Financial Highlights 12 Operating Highlights 14 Management Commentary 15 Vibrant Outlook 16 Corporate Overview 18 Shareholding 22 Contact Us 23 DISCLAIMER: This presentation
Slide 6: Dr. Lal PathLabs – At a Glance
Dr. Lal PathLabs – At a Glance 12% 15% Zero Professionally managed operations; 7 decades of experience in the world of NO. 1 3 Year Revenue 3-Year PAT Net Debt BRANDED diagnostics CAGR CAGR NATIONAL 60% Well diversified outside home market of ‘Delhi NCR’ DIAGNOSTICS ~67% CHAIN WITH Revenue Contribut
Slide 7: Overview of Dr. Lal PathLabs
Overview of Dr. Lal PathLabs Established brand Pan-India integrated Varied Offerings Unique and successful coverage operating model 216 clinical labs (including National Reference Lab at Catalogue of 455 test panels, Scalable model integrated Established consumer Delhi and Regional Reference 2,537 p
Slide 8: Update on COVID-19
Update on COVID-19 NRL, Rohini amongst the first set of private Sample collection enabled through mobile labs to start COVID 19 testing vans and booths 7
Slide 9: Update on COVID-19
Update on COVID-19 Commissioned BSL 2 Lab within a record Logistics ensured that the samples kept time for capacity augmentation moving despite the nationwide lockdown Donation of Rs 1 Crore to PM CARES fund to help the government in its fight against COVID-19 8
Slide 10: COVID-19 - Impact on DLPL & Response
COVID-19 - Impact on DLPL & Response Restriction on movement of • Samples Liaising with local administration to facilitate smooth flow of operations as diagnostics comes under essential services. • Materials Stocked up adequately with reagents and other supplies • Employees Continuous digital commun
Slide 11: Key Performance Highlights
Key Performance Highlights In Q4 FY20, patient volumes increased by 2.1% led by higher growth in the Rest of India market, further supported by stable momentum in the other regions. The performance for the second fortnight of Mar’20 has been adversely impacted by the nationwide lockdown due to COVID
Slide 12: Financials
Financials Q4 FY20 Q4 FY20 Q4 FY19 Gr % Gr % FY20 FY20 FY19 Gr % Gr % Particulars (Rs. Cr.) (With IND- (W/O IND- (W/O IND- (With IND (W/O IND- (With IND- (W/O IND- (W/O IND- (With IND (W/O IND- AS 116) AS 116) AS 116) AS 116) AS 116) AS 116) AS 116) AS 116) AS 116) AS 116) Revenue 301.7 301.7 301.1
Slide 13: Financial Highlights
Financial Highlights All figures in Rs. Crore • Revenue growth in Q4 FY20 stood at 0.2%, at Rs. 301.7 crore. This was contributed by: 301.1 301.7 – Continued momentum in volumes, which grew by 2.1% and – Adverse Impact caused by lockdown in second Revenue fortnight of Mar’20 • Realisation per patien
Slide 14: Financial Highlights
Financial Highlights All figures in Rs. Crore • PBT for Q4 FY20 came in at Rs. 45.4 crore vs. Rs. 69.2 crore in the corresponding quarter of last year, representing a decline of 69.2 34.4% 45.4 • Q4 FY20 PBT margin stood at 15%, as against 23% in the same PBT period of last year • PBT for Q4 FY 20 i
Slide 15: Operating Highlights
Operating Highlights No. of Clinical Laboratories No. of PSCs No. of PUPs 216 3,095 6,995 193 200 2,569 6,426 2,153 5,624 FY18 FY19 FY20 FY18 FY19 FY20 FY18 FY19 FY20 No. of Patients No. of Samples 19.4 47.7 17.6 41.8 15.2 34.7 13.3 29.3 FY17 FY18 FY19 FY20 FY17 FY18 FY19 FY20 14
Slide 16: Management Commentary
Management Commentary Commenting on the results announcement, Dr. Arvind Lal – Executive Chairman “We are in an unprecedented and difficult times. These times are not only impacting the current financial year but impacted Q4FY20 results as well not just for Dr. Lal Pathlabs, but for the entire natio
Slide 17: Vibrant Outlook
Vibrant Outlook Strongly develop Rest of India geographies, through Kolkata National Laboratory and cluster city approach for attractive markets Target to grow Evaluate best fit inorganic Deeper Penetration within the ahead opportunities North, East & Central Indian of the markets industry Higher co
Slide 18: Leveraging digital to make life easier for patient
Leveraging digital to make life easier for patient Logistics Lab Operations Business Digital Lab e-Commerce Mobile app Automation Automation Continuity Plan • Self Registration • Online test / health • Test booking, view • Field Executive • Totally integrated • ‘Multi Site’ model Kiosk for patients
Slide 19: Corporate Overview
Corporate Overview DLPL Strategy for future growth Experienced Management team 18
Slide 20: DLPL Strategy for future growth
DLPL Strategy for future growth 1 2 Strengthen Expansion in Existing Offering Operations 4 3 Expand management of Geographic hospital based expansion and clinical laboratories 19
Slide 21: DLPL Strategy for future growth
DLPL Strategy for future growth Expand management of hospital Strengthen Existing Operations Expansion in Offering Geographic expansion based and clinical laboratories Boosting quality & reliability Improve breadth of Tap incremental contracts for Focus city approach standards diagnostic testing in
Slide 22: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Bharath Uppiliappan Ved Prakash Goel Executive Chairman Managing Director Whole-time Director Chief Executive Officer Chief Financial Officer Shankha Banerjee Munender Soperna Rajat Kalra Manoj Garg Company Sec
Slide 23: Shareholding as of 31st March, 2020
Shareholding as of 31st March, 2020 20.0% FIIs 13.7% 56.8% Others Promoter and Promoter Group 9.5% Mutual Funds* *Mutual Funds includes Alternate Investment Funds as well 22
Slide 24: Contact Us
Contact Us About Dr. Lal PathLabs Limited (DLPL) Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests